Literature DB >> 12943934

Alterations of mitochondrial function and correlations with personality traits in selected major depressive disorder patients.

Ann Gardner1, Anna Johansson, Rolf Wibom, Inger Nennesmo, Ulrika von Döbeln, Lars Hagenfeldt, Tore Hällström.   

Abstract

BACKGROUND: Increased occurrence of several physical conditions has been reported in patients with depressive disorders. Various physical conditions and depressive disorder have been reported in patients with mitochondrial disorders. The aim of this study was to investigate mitochondrial function in selected depressed patients in search of an aetiological or pathophysiological factor common to both depression and physical symptoms.
METHODS: Muscle biopsy was performed in 28 patients with a lifetime prevalence of major depressive disorder (MDD), and at least three chronic physical conditions that have been reported to be common in depressive as well as in mitochondrial disorders. Morphologic and biochemical investigations including mitochondrial ATP production rate (MAPR) by the bioluminometric method, spectrophotometric analyses of mitochondrial enzymes, and long-PCR and Southern blot techniques to detect mitochondrial DNA (mtDNA) deletions were performed. The Karolinska Scales of Personality (KSP) with 15 scales assessing vulnerability to psychopathology was filled in by 21 patients.
RESULTS: Decreases of MAPR and enzyme ratios were found in the patients in comparison with controls (P<0.01). Deletions of mtDNA assessed with long-PCR were more frequent in patients than in controls (chi-square test P<0.05). Correlations were found between MAPR and the KSP scales 'Somatic Anxiety', 'Psychasthenia', and 'Suspicion' (P<0.01). LIMITATIONS: Results cannot be compared with previous studies, and cannot be generalized to all MDD patients. Individually matched controls were not available.
CONCLUSIONS: The results suggest that mitochondrial dysfunction is associated with vulnerability to psychopathology in this selected patient group.

Entities:  

Mesh:

Year:  2003        PMID: 12943934     DOI: 10.1016/s0165-0327(02)00067-8

Source DB:  PubMed          Journal:  J Affect Disord        ISSN: 0165-0327            Impact factor:   4.839


  78 in total

Review 1.  Advances in understanding mechanisms and therapeutic targets to treat comorbid depression and cardiovascular disease.

Authors:  Brittany S Pope; Susan K Wood
Journal:  Neurosci Biobehav Rev       Date:  2020-06-26       Impact factor: 8.989

2.  Chronic variable stress impairs energy metabolism in prefrontal cortex and hippocampus of rats: prevention by chronic antioxidant treatment.

Authors:  Bárbara Tagliari; Cristie G Noschang; Andréia G K Ferreira; Otávio A Ferrari; Luciane R Feksa; Clovis M D Wannmacher; Carla Dalmaz; Angela T S Wyse
Journal:  Metab Brain Dis       Date:  2010-05-27       Impact factor: 3.584

Review 3.  New drug targets in depression: inflammatory, cell-mediated immune, oxidative and nitrosative stress, mitochondrial, antioxidant, and neuroprogressive pathways. And new drug candidates--Nrf2 activators and GSK-3 inhibitors.

Authors:  Michael Maes; Zdenĕk Fišar; Miguel Medina; Giovanni Scapagnini; Gabriel Nowak; Michael Berk
Journal:  Inflammopharmacology       Date:  2012-01-24       Impact factor: 4.473

4.  Candidate hippocampal biomarkers of susceptibility and resilience to stress in a rat model of depression.

Authors:  Kim Henningsen; Johan Palmfeldt; Sofie Christiansen; Isabel Baiges; Steffen Bak; Ole Nørregaard Jensen; Niels Gregersen; Ove Wiborg
Journal:  Mol Cell Proteomics       Date:  2012-02-06       Impact factor: 5.911

Review 5.  Role of immune-inflammatory and oxidative and nitrosative stress pathways in the etiology of depression: therapeutic implications.

Authors:  George Anderson; Michael Berk; Olivia Dean; Steven Moylan; Michael Maes
Journal:  CNS Drugs       Date:  2014-01       Impact factor: 5.749

Review 6.  Multivariate meta-analyses of mitochondrial complex I and IV in major depressive disorder, bipolar disorder, schizophrenia, Alzheimer disease, and Parkinson disease.

Authors:  L Holper; D Ben-Shachar; J J Mann
Journal:  Neuropsychopharmacology       Date:  2018-05-16       Impact factor: 7.853

Review 7.  A mitochondrial bioenergetic basis of depression.

Authors:  N Jennifer Klinedinst; William T Regenold
Journal:  J Bioenerg Biomembr       Date:  2014-09-28       Impact factor: 2.945

8.  Brain cytochrome-c-oxidase as a marker of mitochondrial function: A pilot study in major depression using NIRS.

Authors:  Lisa Holper; Martin J Lan; Patrick J Brown; Elizabeth M Sublette; Ainsley Burke; John J Mann
Journal:  Depress Anxiety       Date:  2019-05-21       Impact factor: 6.505

9.  Treatment with tianeptine induces antidepressive-like effects and alters the neurotrophin levels, mitochondrial respiratory chain and cycle Krebs enzymes in the brain of maternally deprived adult rats.

Authors:  Franciela P Della; Helena M Abelaira; Gislaine Z Réus; Maria Augusta B dos Santos; Débora B Tomaz; Altamir R Antunes; Giselli Scaini; Meline O S Morais; Emilio L Streck; João Quevedo
Journal:  Metab Brain Dis       Date:  2013-01-18       Impact factor: 3.584

10.  Plasma and erythrocyte fatty acid patterns in patients with recurrent depression: a matched case-control study.

Authors:  Johanna Assies; François Pouwer; Anja Lok; Roel J T Mocking; Claudi L H Bockting; Ieke Visser; Nico G G M Abeling; Marinus Duran; Aart H Schene
Journal:  PLoS One       Date:  2010-05-14       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.